Fact sheet
Reaching more patients with cell therapy

Reaching more patients with cell therapy


The Bristol Myers Squibb Cell Therapy Organization has spent 20+ years in pursuit of unlocking the full potential of cell therapy and delivering transformative treatments to patients with blood cancers and beyond. We have treated more than 15,000 patients and built a network of hundreds of academic and community centers that offer access to this innovative treatment option.

 

Our bold vision for the future is one in which hundreds of thousands of patients are treated with cell therapy. This requires not just scaling research, development and manufacturing, but changing the face of delivery, so that the patients we reach reflect the realities of the diseases we treat.
 

Today

Group

Only 2 in 10 patients
eligible for cell
therapy treatment
are receiving it

Medical building

CAR T cell therapy is only available in <4% of U.S. healthcare centers1

Dollar icon

Patients with income
<$40K are ~60% less
likely to receive
treatment than those
with income ≥$100K2

Medical head

Data recently published
showed Black and
Hispanic patients are
50% less likely to
receive CAR T
treatment than other
patient populations2

Creating a better tomorrow

At BMS, we believe it is imperative to expand cell therapy treatment by challenging current practices, assumptions and barriers that limit access along certain geographic, demographic or socioeconomic lines.

Partnering with stakeholders from across the healthcare ecosystem, we’re leading initiatives designed to ease patient burden without sacrificing patient safety, expand access in underserved communities, and offer support for those who have been prescribed our medicines.


In June 2025, the U.S. Food and Drug Administration (FDA) approved label updates for all CAR T cell therapies reducing certain monitoring requirements. Together, these updates reflect an increased confidence and safety profile of cell therapy and will help to ease known barriers to cell therapy treatment and administration.

Bringing CAR T treatment closer to patients

BMS is committed to connecting patients, caregivers, and healthcare providers in communities around the United States to cell therapy near them.

 

Right now, we have more than 150 treatment centers across the U.S. and our network is growing. BMS is focused on rapidly expanding the geographic footprint of cell therapy, with a renewed effort to add community cancer centers nationwide, helping further reduce travel time and duration of stay away from home, loves ones and work.

U.S. map
Pointer

Visit our treatment center locator to find a treatment center near you.

Supporting patients’ CAR T journey

For patients who have been prescribed a BMS CAR T cell therapy, but may require additional support, there are services available. 
 

Operator icon

On-demand patient guidance:
enrolled patients will be assigned
a personal Patient Support
Navigator to provide customized
solutions and support throughout
their treatment journey.

Circle group

Logistical support: eligible
patients* and a caregiver can
receive transportation, lodging,
and meal assistance during the
CAR T process. 

Dollar icon

Financial assistance: through
a Copay Assistance Program,
out-of-pocket expenses for
commercially insured patients
may be covered for BMS CAR T
cell therapy products.*^

Pointer

Visit the Cell Therapy 360® patients and caregivers page for more information.

References

  1. Odstrcil, M., Lee, C., Sobieski, C., Weisdorf, D., Couriel, D. (2024). Access to CAR T-cell therapy: Focus on diversity, equity and inclusion. Blood Reviews. Volume 63, Pages 1-7. https://www.sciencedirect.com/science/article/pii/S0268960X23000978?via%3Dihub
  2. Ahmed, N., Sun, F., Teigland, C., Kilgore, K. M., Mohammadi, I., Chambers, J., Dieyi, C., Feng, C., Osborn, J., Fu, C., Gergis, U. (2024). Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers. Transplantation and Cellular Therapy. Volume 30, Issue 7, Pages 714-725, ISSN 2666-6367. https://doi.org/10.1016/j.jtct.2024.04.017

* Eligibility requirements apply.
^ The program is not available for patients who are enrolled in Medicare, Medicaid, TRICARE, the Veterans Affairs (VA), or any other federal or state healthcare program. The program will cover the out-of-pocket expenses of the Bristol Myers Squibb product only. Limitations apply. It does not cover the costs of any other healthcare provider charges or any other treatment costs. Patients are responsible for non-drug-related out-of-pocket costs. Additional eligibility requirements may apply. Bristol Myers Squibb reserves the right to rescind, revoke, or amend this program without notice.


BMS logo
Cell Therapy Organization